A recent study suggests that people who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional diet and exercise plans.
Published data in a prominent health publication points out that while overweight individuals often shed about a fifth of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using these treatments need to be cognizant of the risk of quick rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.
Such speed of regain means a reversion to starting mass in about one and a half years.
Comparing Treatments
The analysis, which looked at dozens of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
The team emphasize that individuals who lose weight through dieting typically experience a slower weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Doctors believe the mode of action of the injections accounts for the amplified rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the body to produce less of its own natural GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement means hunger is uncontrolled, making binge eating far more likely."
A Chronic Issue?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the treatment is often life-long.
This view is reinforced by drug manufacturers, who note that the results "underscore the persistent nature of obesity," similar to managing diseases like diabetes.
Patient Accounts
People who have stopped the medication describe a intense resurgence of appetite.
"I experienced a switch activating and you become extremely hungry," said a patient.
This difficulty is worsened if individuals have not developed permanent dietary or behavioural changes during treatment.
Growing Adoption
Figures indicate that a significant number of people in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is higher among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
Finally, experts stress that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent cure and long-term success hinges on integrated lifestyle support.
